Hologic — May 1, 2025 release

Financial Guidance for the Third Quarter and Full Fiscal Year 2025 “We are maintaining our full-year revenue guidance, but lowering our non-GAAP EPS guidance slightly based on tariffs and geopolitical conditions,” said Karleen Oberton, Hologic’s Chief Financial Officer. Hologic’s financial guidance for the third quarter and full year 2025 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.25%, and diluted shares outstanding of approximately 228 million for the full year.  Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2025 as in fiscal 2024.  Organic revenue guidance for fiscal 2025 is in constant currency and excludes the divested blood screening and SSI ultrasound imaging businesses.  Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition.  In fiscal 2025, revenue from the acquired Endomagnetics business becomes organic in August.  Revenue from the acquired Gynesonics business will be excluded from organic revenue for all of fiscal 2025.  Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in diagnostics.     Current Guidance   Previous Guidance       Guidance $   Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic % Increase (Decrease) Organic excluding COVID-19 % Increase (Decrease)   Guidance $   Fiscal